The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.
Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus™; on market and estimated to be a billion dollar plus product), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches. Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. Kling Biotherapeutics is progressing a unique pipeline of oncology programs with KBA1412, a first-in-class CD9 antibody, being tested in a Phase 1 clinical trial.